The value of serum prostate specific antigen determinations before and after radical prostatectomy
- PMID: 2467013
- DOI: 10.1016/s0022-5347(17)41037-8
The value of serum prostate specific antigen determinations before and after radical prostatectomy
Abstract
We evaluated serum prostate specific antigen before and after radical prostatectomy. In 100 consecutive patients who underwent radical prostatectomy, preoperative prostate specific antigen levels tended to increase with the increasing severity of pathological stage. However, even at levels of greater than 10 ng. per ml. the positive and negative predictive values (78 and 61 per cent, respectively) of prostate specific antigen to predict extracapsular disease were not sufficient to make this test useful alone for staging. In theory, after radical prostatectomy prostate specific antigen should be zero if no remaining prostatic tissue is present. Tests of precision and analytical sensitivity in our laboratory using a commercial prostate specific antigen assay revealed that a value of 0.4 ng. per ml. or more is different from zero at a greater than 95 per cent confidence level. With this guideline we evaluated the meaning of prostate specific antigen levels 3 to 6 months after radical prostatectomy in 59 men. Among men whose prostate specific antigen level was less than 0.4 ng. per ml. only 9 per cent demonstrated recurrence as evidenced by the development of positive bone scan or progressively elevated prostate specific antigen levels within 6 to 50 months. Alternatively, in men whose 3 to 6-month prostate specific antigen level was 0.4 ng per ml. or more there was evidence of recurrence in 100 per cent within 6 to 49 months (p less than 0.0001). Progressively elevated (more than 0.4 ng. per ml.) prostate specific antigen levels preceded recurrence from 12 to 43 months in all 6 patients who had positive bone scans, while increasing prostate specific antigen levels since radical prostatectomy have continued from 9 to 65 months in the 11 patients who have no radiological evidence of recurrent disease to date. Prostatic acid phosphatase serum values after radical prostatectomy were not useful to predict persistent disease. Prostate specific antigen values 3 to 6 months after radical prostatectomy are a sensitive indicator of persistent disease after radical prostatectomy and often precede other evidence of this occurrence by many years. This fact may alter concepts about surgical results, and possibly shorten and sharpen clinical studies involving adjuvant therapy after radical prostatectomy.
Similar articles
-
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.J Urol. 1989 May;141(5):1076-83. doi: 10.1016/s0022-5347(17)41175-x. J Urol. 1989. PMID: 2468795
-
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.J Urol. 1988 Apr;139(4):766-72. doi: 10.1016/s0022-5347(17)42630-9. J Urol. 1988. PMID: 2451037
-
Clinical use of prostate specific antigen in patients with prostate cancer.J Urol. 1989 Oct;142(4):1011-7. doi: 10.1016/s0022-5347(17)38972-3. J Urol. 1989. PMID: 2477559
-
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.J Urol. 1991 May;145(5):907-23. doi: 10.1016/s0022-5347(17)38491-4. J Urol. 1991. PMID: 1707989 Review.
-
Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation.Front Radiat Ther Oncol. 2002;36:35-42. doi: 10.1159/000061327. Front Radiat Ther Oncol. 2002. PMID: 11842753 Review. No abstract available.
Cited by
-
The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy.Int Urol Nephrol. 1995;27(3):319-24. doi: 10.1007/BF02564769. Int Urol Nephrol. 1995. PMID: 7591597
-
Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis.Can Urol Assoc J. 2015 Jan-Feb;9(1-2):E14-21. doi: 10.5489/cuaj.2147. Can Urol Assoc J. 2015. PMID: 25624961 Free PMC article.
-
Continence rate and oncological feasibility after total transurethral resection of the prostate as an alternative therapy for the treatment of prostate cancer: a pilot study.Int Neurourol J. 2011 Dec;15(4):222-7. doi: 10.5213/inj.2011.15.4.222. Epub 2011 Dec 31. Int Neurourol J. 2011. PMID: 22259737 Free PMC article.
-
Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity.Oncoimmunology. 2012 Oct 1;1(7):1084-1094. doi: 10.4161/onci.20924. Oncoimmunology. 2012. PMID: 23170256 Free PMC article.
-
Assessment of biochemical recurrence of prostate cancer (Review).Int J Oncol. 2019 Dec;55(6):1194-1212. doi: 10.3892/ijo.2019.4893. Epub 2019 Oct 4. Int J Oncol. 2019. PMID: 31638194 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical